GlobeNewswire by notified

Publication of transparency notifications

Share

Ghent, July 15, 2021 (GLOBE NEWSWIRE) -- Press release - regulated information

Publication of transparency notifications
(Article 14(1) of the Law of 2 May 2007 on the disclosure of large shareholders in issuers whose shares are admitted to trading on a regulated market)

Ghent, BELGIUM 15July 2021, 07:00 CEST Biotalys (Euronext - BTLS), an AgTech company focused on addressing food protection challenges to enable a more sustainable and safer food supply, announces today, in accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings in issuers whose shares are admitted to trading on a regulated market (the ‘Belgian Transparency Act’), that it has received transparency notifications from Ackermans & van Haaren NV, Gimv NV, Adviesbeheer Gimv Venture Capital 2010 NV and Biotech Fonds Vlaanderen NV, Sofinnova Partners S.A.S., ParticipatieMaatschappij Vlaanderen NV, K&E BV, Biovest NV, Madeli participaties B.V. and Agri Investment Fund C.V.B.A.

1.   Ackermans & van Haaren NV


Ackermans & van Haaren NV has announced that, on 2 July 2021, it held 4,016,281 shares of Biotalys NV, representing 13.38% of the total number of voting rights.

The notification dated 9 July 2021 contains the following information:

  • Reason for the notification: holding of voting securities upon first admission to trading
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • Ackermans & van Haaren NV, Begijnenvest 113, 2000 Antwerp
    • Stichting Administratiekantoor “Het Torentje”, Parklaan 34, 3018 BC Rotterdam (NL)
  • Date on which the threshold was crossed: 2 July 2021
  • Threshold that is crossed: 10%
  • Denominator: 30,020,387
  • Notified details:

Voting rightsPrevious notificationAfter the transaction
# of voting rights# of voting rights% of voting rights
Holders of voting rightsLinked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
Stichting Administratiekantoor “Het Torentje”000.00%0.00%
Ackermans & van Haaren4,016,281013.38%0.00%
TOTAL4,016,281013.38%0.00%
  • Chain of control over Ackermans & van Haaren NV
    • (i) Ackermans & van Haaren NV is directly controlled by Scaldis Invest NV
    • (ii) Scaldis Invest NV is directly controlled by Belfimas NV
    • (iii) Belfimas NV is directly controlled by Celfloor S.A.
    • (iv) Celfloor S.A. is directly controlled by Apodia International Holding B.V.
    • (v) Apodia International Holding B.V. is directly controlled by Palamount S.A.
    • (vi) Palamount S.A. is directly controlled by Stichting administratiekantoor “Het Torentje”
    • (vii) Stichting administratiekantoor “Het Torentje” is the ultimate controlling shareholder.

In accordance with article 11, §1 of the Act of 2 May 2007, stichting administratiekantoor “Het Torentje” acts in its own name and on behalf of the companies set forth under (ii) up to and including (vi).

2.   Gimv NV, Adviesbeheer Gimv Venture Capital 2010 NV and Biotech Fonds Vlaanderen NV


Gimv NV, Adviesbeheer Gimv Venture Capital 2010 NV and Biotech Fonds Vlaanderen have announced that, on 2 July 2021, combined they held 4,307,393 shares of Biotalys NV, representing 14.35% of the total number of voting rights.

The notification dated 14 July 2021 contains the following information:

  • Reason for the notification: holding of voting securities upon first admission to trading
  • Notification by:
    • a parent undertaking or a controlling person
    • persons acting in concert
  • Persons subject to the notification requirement:
    • Gimv NV, Karel Oomsstraat 37, 2018 Antwerp
    • Adviesbeheer Gimv Venture Capital 2010 NV, Karel Oomsstraat 37, 2018 Antwerp
    • Biotech Fonds Vlaanderen NV, Oude Graanmarkt 63, 1000 Brussels
  • Date on which the threshold was crossed: 2 July 2021
  • Threshold that is crossed: 10%
  • Denominator: 30,020,387
  • Notified details:
Voting rightsPrevious notificationAfter the transaction
# of voting rights# of voting rights% of voting rights
Holders of voting rightsLinked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
Gimv NV1,586,01005.28%0.00%
Adviesbeheer Gimv Venture Capital 2010 NV226,57000.75%0.00%
Biotech Fonds Vlaanderen2,494,81308.31%0.00

%

TOTAL4,307,393014.35%0.00%
  • Gimv NV is not a controlled entity within the meaning of Articles 1:14 and 1:16 of the Belgian Companies and Associations Code and holds 100% of the shares in Adviesbeheer Gimv Venture Capital 2010 NV.
  • PMV holds 100% of the shares in Biotech Fonds Vlaanderen NV, but the management of this participation has been transferred to Gimv NV. A possible divestment shall be submitted to Biotech Fonds Vlaanderen NV, but if this meets certain pre-defined criteria the necessary mandates shall be provided. By consequence, persons are acting in concert.

3.   SofinnovaPartners S.A.S.


Sofinnova Partners S.A.S. has announced that, on 2 July 2021, it held 4,226,962 shares of Biotalys NV, representing 14.08% of the total number of voting rights.

The notification dated 9 July 2021 contains the following information:

  • Reason for the notification: holding of voting securities upon first admission to trading
  • Notification by: a person that notifies alone
  • Persons subject to the notification requirement: Sofinnova Partners S.A.S., 7-11 Boulevard Haussmann - 75009 - Paris (France)
  • Date on which the threshold was crossed: 2 July 2021
  • Threshold that is crossed: 10%
  • Denominator: 30,020,387
  • Notified details:

Voting rightsPrevious notificationAfter the transaction
# of voting rights# of voting rights% of voting rights
Holders of voting rightsLinked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
Sofinnova Partners S.A.S.4,226,962014.08%0.00%
TOTAL4,226,962014.08%0.00%
  • Sofinnova Partners S.A.S. is not a controlled entity within the meaning of Articles 1:14 and 1:16 of the Belgian Companies and Associations Code.
  • Sofinnova Partners S.A.S. is the management company of Sofinnova Industrial Biotech I (a professional capital investment fund under French law) qualifying as collective investment undertaking in the meaning of article 9 § 2 of the royal decree of 14 February 2007, and exercises the voting rights attached to shares owned by Sofinnova Industrial Biotech at its own discretion without any instructions from the fund.

4.   ParticipatieMaatschappij Vlaanderen NV

ParticipatieMaatschappij Vlaanderen NV has announced that, on 2 July 2021, it held 2,494,813 shares of Biotalys NV, representing 8.31% of the total number of voting rights.

The notification dated 14 July 2021 contains the following information:

  • Reason for the notification: holding of voting securities upon first admission to trading
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • Vlaamse Gewest (Flemish Region), Martelaarsplein 19, 1000 Brussels
    • ParticipatieMaatschappij Vlaanderen NV, Oude Graanmarkt 63, 1000 Brussels
  • Date on which the threshold was crossed: 2 July 2021
  • Threshold that is crossed: 5%
  • Denominator: 30,020,387
  • Notified details:

Voting rightsPrevious notificationAfter the transaction
# of voting rights# of voting rights% of voting rights
Holders of voting rightsLinked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
Vlaamse Gewest000.00%0.00%
ParticipatieMaatschappij Vlaanderen NV2,494,81308.31%0.00%
TOTAL2,494,81308.31%0.00%
  • The Flemish Region (het Vlaamse Gewest) holds 100% of the shares in ParticipatieMaatschappij Vlaanderen NV (PMV NV). PMV NV holds 100% of the shares in Biotech Fonds Vlaanderen NV which on its turen holds 8,31 % of the shares in Biotalys. This participation however is managed by Gimv NV. A possible divestment shall be submitted to Biotech Fonds Vlaanderen NV, but if this meets certain pre-defined criteria the necessary mandates shall be provided.

5.   K&E BV


K&E BV has announced that, on 2 July 2021, it held 1,867,837 shares of Biotalys NV, representing 6.22% of the total number of voting rights.

The notification dated 14 July 2021 contains the following information:

  • Reason for the notification: holding of voting securities upon first admission to trading
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • Koen Quaghebeur
    • Els Paesmans
    • K&E BV, Lichtenberglaan 2019, 3800 Sint-Truiden
  • Date on which the threshold was crossed: 2 July 2021
  • Threshold that is crossed: 5%
  • Denominator: 30,020,387
  • Notified details:
Voting rightsPrevious notificationAfter the transaction
# of voting rights# of voting rights% of voting rights
Holders of voting rightsLinked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
Koen Quaghebeur000.00%0.00%
Els Paesmans000.00%0.00%
K&E BV1,867,83706.22%0.00%
TOTAL1,867,83706.22%0.00%
  • K&E BV is controlled by Mr. Koen Quaghebeur (50%) and Mrs. Els Paesmans (50%).

6.   BiovestNV

Biovest NV has announced that, on 2 July 2021, it held 2,048,798 shares of Biotalys NV, representing 6.82% of the total number of voting rights.

The notification dated 14 July 2021 contains the following information:

  • Reason for the notification: holding of voting securities upon first admission to trading
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • Stefan Mariën
    • Sniper Invest SA, Route d’Arlon 19-21 L 8009 Strassen Luxembourg
    • Frederic Mariën
    • Fontana Invest SA, Route d’Arlon 19-21 L 8009 Strassen Luxembourg
    • Robin Devos
    • Radium Invest SA, Route d’Arlon 19-21 L 8009 Strassen Luxembourg
    • RMM SA, Route d’Arlon 19-21 L 8009 Strassen Luxembourg
    • Biovest NV, Karel van de Woestijnestraat 3, 9000 Ghent
  • Date on which the threshold was crossed: 2 July 2021
  • Threshold that is crossed: 5%
  • Denominator: 30,020,387
  • Notified details:

Voting rightsPrevious notificationAfter the transaction
# of voting rights# of voting rights% of voting rights
Holders of voting rightsLinked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
Stefan Mariën000.00%0.00%
Sniper Invest SA000.00%0.00%
Frederic Mariën000.00%0.00%
Fontana Invest SA000.00%0.00%
Robin Devos000.00%0.00%
Radium Invest SA000.00%0.00%
RMM SA000.00%0.00%
Biovest NV2,048,79806.82%0.00%
TOTAL2,048,79806.82%0.00%
  • Biovest NV is 100% owned by RMM SA, which is ultimately owned by Sniper Invest SA (ultimately owned by Stefan Mariën), Fontana Invest SA (ultimately owned by Frederic Mariën), and Radium Invest SA (ultimately owned by Robin Devos), each for one third.

7.   Madeli participaties B.V.


Madeli participaties B.V. has announced that, on 2 July 2021, it held 1,948,798 shares of Biotalys NV, representing 6.49% of the total number of voting rights.

The notification dated 12 July 2021 contains the following information:

  • Reason for the notification: holding of voting securities upon first admission to trading
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • Madeli Participaties BV, Leeuwenhoekweg 46, 2661 CZ Bergschenhoek (NL)
    • Fran-I BV, Leeuwenhoekweg 46, 2661 CZ Bergschenhoek (NL)
    • BBG-II BV, Leeuwenhoekweg 46, 2661 CZ Bergschenhoek (NL)
    • Ermati-III BV, Leeuwenhoekweg 46, 2661 CZ Bergschenhoek (NL)
    • Maurits de Ruiter
    • Wouter de Ruiter
    • Henk de Ruiter
  • Date on which the threshold was crossed: 2 July 2021
  • Threshold that is crossed: 5%
  • Denominator: 30,020,387
  • Notified details:
Voting rightsPrevious notificationAfter the transaction
# of voting rights# of voting rights% of voting rights
Holders of voting rightsLinked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
Maurits de Ruiter000.00%0.00%
Wouter de Ruiter000.00%0.00%
Henk de Ruiter000.00%0.00%
Madeli Participaties BV1,948,79806.49%0.00%
TOTAL1,948,79806.49%0.00%
  • Madeli Participaties BV is controlled by Madeli BV. The latter company is controlled for 33.33% each by the following entities: Fran-I BV (controlled by Maurits de Ruiter), BBG-II BV (controlled by Wouter de Ruiter) en Ermati-III BV (controlled by Henk de Ruiter).

8.   Agri Investment Fund C.V.B.A

Agri Investment Fund C.V.B.A. has announced that, on 2 July 2021, it held 2,158,708 shares of Biotalys NV, representing 7.19% of the total number of voting rights.

The notification dated 8 July 2021 contains the following information:

  • Reason for the notification: holding of voting securities upon first admission to trading
  • Notification by: a parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • HBB V.Z.W., Diestsevest 40, 3000 Leuven
    • BB-Patrim C.V.B.A., Diestsevest 40, 3000 Leuven
    • M.R.B.B. C.V.B.A., Diestsevest 32 5b, 3000 Leuven
    • Agri Investment Fund C.V.B.A., Diestsevest 32 5b, 3000 Leuven
  • Date on which the threshold was crossed: 2 July 2021
  • Threshold that is crossed: 5%
  • Denominator: 30,020,387
  • Notified details:

Voting rightsPrevious notificationAfter the transaction
# of voting rights# of voting rights% of voting rights
Holders of voting rightsLinked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities
HBB V.Z.W.000.00%0.00%
Agri Investment Fund C.V.B.A.2,158,70807.19%0.00%
TOTAL2,158,7087.19%0.00%
  • HBB V.Z.W. holds 100% in BB-Patrim C.V.B.A
  • BB-Patrim C.V.B.A. holds 53.5% in M.R.B.B. C.V.B.A.
  • M.R.B.B. C.V.B.A. holds 100% in Agri Investment Fund C.V.B.A.

The respective transparency notifications can be found on www.biotalys.com/investors.

About Biotalys

Biotalys is an Agricultural Technology (AgTech) company focused on addressing food protection challenges with proprietary protein-based biocontrol solutions and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys has developed a strong and diverse pipeline of effective products with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and was listed on Euronext Brussels on 2 July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.

For further information, please contact

Toon Musschoot, Strategic Communications Manager
T: +32 (0)9 274 54 00
E: Toon.Musschoot@biotalys.com

Consilium Strategic Communications
Amber Fennell, Chris Gardner, Chris Welsh
T: +44 (0)203 709 5700
E: Biotalys@consilium-comms.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Baltic Horizon Fund consolidated audited results for 202329.3.2024 10:35:00 CET | Press release

Management Board of Northern Horizon Capital AS has approved the audited financial results of Baltic Horizon Fund (the Fund) for the year 2023. The financial results remained unchanged compared to the preliminary disclosure on 15 February 2024. Executing our strategy In a challenging economic landscape characterized by inflation, interest rate volatility, and recent geopolitical events, the Fund has assessed various strategic options to navigate these complexities and ensure future growth. Over the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from the centrally located ‘Modern City Life’ multi-fu

Progress on ABN AMRO share buyback programme 22 – 28 March 202429.3.2024 08:00:00 CET | Press release

Progress on ABN AMRO share buyback programme 22 – 28 March 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 22 March 2024 up to and including 28 March 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.47 for a total amount of €46,409,760.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme. To date the total consideration for shares and depositary receipts repurchased amounts to €279,519,000.00 representing 55.9% of the overall share buyback programme. ABN AMRO Press Office pressrelations@nl.abnamro.com +31 20 6288900ABN AMRO Investor Relations investorrelations@nl.abnamro.com +31 20 6282282 This press release is published by ABN AMRO Ba

Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind29.3.2024 07:00:00 CET | Press release

Press release Brussels, 29 March 2024 Regulated information – Inside information Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind On 20 November 2023, Orange Belgium SA (the “Company”) received notification from Nethys SA (“Nethys”) of its wish to contribute its 25% + 1 shareholding in VOO Holding SA (“VOO”) to the capital of the Company, provided that such contribution results in Nethys holding at least 11% of the Company's share capital (after contribution), pursuant to the provisions of the shareholders' agreement entered into by and between the Company, Atlas Services Belgium SA (“ASB”) and Nethys on 2 June 2023. Nethys can be considered a “related” party to the Company within the meaning of the IAS standards, as it has significant influence over VOO within the meaning of IAS and VOO is part of the group to which the Company belongs. Date and value of the planned t

McWhorter Foundation Combats Nelson Peltz’s Outdated Ideologies and Advocates for Sustainable Inclusivity In Corporate Leadership29.3.2024 06:59:56 CET | Press release

PALM BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- C.K. McWhorter, chairman of the McWhorter Foundation, voices concerns over outdated perspectives in corporate leadership, exemplified by recent remarks from Nelson Peltz regarding Disney's film direction. After encountering instances of racism and exclusivity on Town of Palm Beach Island (known as home to Jeffrey Epstein, Nelson Peltz and others), McWhorter reflects on the disconnect between elite boardroom discussions and the realities faced by diverse communities. While briefly meeting Nelson Peltz and shaking hands after both departed separate lunches, McWhorter initially respected his insights. However, recent comments made by Peltz suggesting Disney should avoid inclusive films have raised eyebrows and prompted McWhorter to speak out. "It's concerning when influential figures like Peltz advocate against inclusivity in entertainment," McWhorter comments. "The future is in diversity and representation, especially as millennial a

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates29.3.2024 05:24:27 CET | Press release

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB1,503 million during 2023. The revenue from pharmaceutical products increased by approximately 58% compared to 2022. The sales revenue of TUOYI® (toripalimab) was approximately RMB919 million, representing an increase of approximately 25% compared to the previous year.Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022. The decrease in R&D expenses was mainly due to the strategic management of R&D investments in certain early-stage pipelines, while optimizing resource all

HiddenA line styled icon from Orion Icon Library.Eye